Aligos Therapeutics, Inc. 8-K

What Happened
Aligos Therapeutics, Inc. filed a Form 8-K (Item 5.02) reporting that on January 29, 2026 the company’s Board appointed Nikhil Aneja as Principal Accounting Officer, effective immediately. Mr. Aneja, age 49, succeeds Lesley Ann Calhoun in the Principal Accounting Officer role; Calhoun continues to serve as Executive Vice President, Chief Operating Officer & Chief Financial Officer. The 8-K was filed on February 4, 2026.

Key Details

• Appointment effective date: January 29, 2026; 8-K filed February 4, 2026 (Item 5.02).
• New appointee: Nikhil Aneja, age 49; previously Vice President, Finance at Aligos since February 2024.
• Prior roles: VP, Corporate Controller at CareDx, Inc. (Dec 2022–Feb 2024); VP Finance & Accounting at Blade Therapeutics (May 2021–Oct 2022); Executive Director, Global Corporate Controller at Global Blood Therapeutics (Sept 2016–May 2021).
• Education and credential: Bachelor of Commerce (University of Delhi); Certified Public Accountant.
• Lesley Ann Calhoun remains EVP, COO & CFO of Aligos (i.e., no change to the CFO role).

Why It Matters
This filing clarifies Aligos’s accounting leadership by naming a dedicated Principal Accounting Officer while keeping the company’s CFO in place. For investors, the change signals continuity in financial oversight (Calhoun remains CFO) and formalizes Mr. Aneja’s role in overseeing accounting and financial reporting, backed by multi-company biopharma finance experience and CPA credentials.